Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swiss chemical and biotechnology company Lonza has granted Genentech a non-exclusive, worldwide license to its GS gene expression system, a technology platform to aid drug development.
Subscribe to our email newsletter
The initial license granted to Genentech allows the US biotechnology company to use the GS system only for R&D purposes. However, the agreement does provide options for Genentech to expand the agreement for commercial purposes.
As part of the agreement, Genentech will pay license fees and milestone payments, the financial terms of which have not been disclosed.
“Lonza is pleased to enter into this agreement with Genentech. We believe that having Lonza’s GS gene expression system selected by one of the leaders in the development and manufacture of biopharmaceuticals underscores the importance of this technology for the efficient production of therapeutic antibodies and recombinant proteins” said Karen Fallen, Lonza’s commercial license manager.